Increased production of human immunodeficiency virus (HIV) in HIV-induced syncytia formation: an efficient infection process.
Syncytia or multinucleated giant-cell formation is one of the major cytopathic effects induced by human immunodeficiency virus (HIV) infection. Cell fusion results from the strong interaction of CD4 molecules on the surface of the uninfected T cells and gp120, an external envelope glycoprotein of HIV on the infected T cells. We studied the production of HIV in fusion cells between MOLT-4 and virus-infected MOLT-4/HIV cells and found that HIV production was enhanced up to three- to fivefold, which showed a good correlation with the appearance and extent of syncytia formation. Blocking the fusion by monoclonal antibody against a binding epitope of CD4 molecule to gp120 decreased the HIV production significantly. Enhancement of HIV production was observed by more than five-fold in comparison with chronically infected cells, which were fusion free 20 hr postcocultivation. Electron microscopic observation also showed the presence of abundant HIV particles inside the fused cells and on the outer surface. AZT blocked the HIV augmentation of fused cells in coculture completely. Southern blot analysis revealed that both integrated and unintegrated HIV DNA were highly accumulated in fusion cells, as compared with fusion-free MOLT-4/HIV cells. Among unintegrated DNA, circular and linear DNA were accumulated to a similar degree. Northern blot hybridization showed that rapid enhancement of all three species of HIV-specific RNA containing genomic (9.2 kb) and subgenomic (4.3 and 1.9 kb) RNAs were found 20 hr postinfection in fusion cells. These data suggest that syncytia formation is an extremely active infection process of HIV, by which multiple rounds of reinfection might take place.
Chowdhury
M I
MI
Department of Virology and Parasitology, Yamaguchi University School of Medicine, Japan.
Koyanagi
Y
Y
Suzuki
M
M
Kobayashi
S
S
Yamaguchi
K
K
Yamamoto
N
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000502:physiology; D015704:CD4 Antigens / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000382:microbiology; D002459:Cell Fusion; D002460:Cell Line; D004279:DNA, Viral / Q000235:genetics; D005784:Gene Amplification; D015726:Giant Cells / Q000382:microbiology* / Q000648:ultrastructure; D016655:HIV Core Protein p24 / Q000096:biosynthesis; D015658:HIV Infections / Q000276:immunology / Q000382:microbiology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D006801:Humans; D051379:Mice; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D014158:Transcription, Genetic; D014776:Virus Cultivation; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D004279:DNA, Viral; D016655:HIV Core Protein p24; D011500:Protein Synthesis Inhibitors; D015215:Zidovudine